- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Optinose Announces Pricing of Public Offering of Common Stock
OptiNose (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000 shares being sold by Optinose and 2,500,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately …
OptiNose (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000 shares being sold by Optinose and 2,500,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $52.3 million to Optinose and approximately $52.3 million to the selling stockholders, after deducting underwriting discounts and before offering expenses.
As quoted in the press release:
In addition, Optinose and the selling stockholders have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 750,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders.
The offering is expected to close on or about June 11, 2018, subject to satisfaction of customary closing conditions. Registration statements relating to these securities were declared effective by the Securities and Exchange Commission on June 6, 2018.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.